Skip to content

Levetiracetam Versus Phenytoin in Management of Pediatric Status Epilepticus

Levetiracetam Versus Phenytoin in Management of Pediatric Status Epilepticus: a Randomized Clinical Trial

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04176887
Enrollment
60
Registered
2019-11-25
Start date
2019-01-01
Completion date
2020-08-01
Last updated
2019-11-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Comparison, the Efficacy of Levetireacetam, Phenytoin, Management of Pediatric Status Epilepticus

Keywords

Levetireacetam, Phenytoin, status epilepticus, children

Brief summary

The study will be conducted on 60 children suffering from status epilepticus who will be admitted to Pediatric Neurology Unit and Pediatric ICU of Tanta Hospital University.

Detailed description

The aim of this work is to compare the efficacy of Levetireacetam and Phenytoin in management of pediatric status epilepticus.

Interventions

The levetiracetam dose is 20- 40 mg/kg by intravenous infusion over 15 minute, a rate of 2-5 mg/kg/minute diluted in 100 ml with 0.9% sodium chloride as a single dose.

DRUGPhenytoin Injection

Phenytoin dose is 20-40 mg/kg/min by intravenous infusion over 30 minute, diluted with 0.9% sodium chloride to a maximum concentration of 10 mg/ml.

Sponsors

Tanta University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
30 Days to 18 Years
Healthy volunteers
No

Inclusion criteria

* Children suffering from convulsive generalized tonic clonic status epilepticus at any age.

Exclusion criteria

* Non convulsive status epilepticus. * Children with known contraindication or allergy to levetireacetam or phenytoin.

Design outcomes

Primary

MeasureTime frameDescription
cessation of convulsion30 minutesseizure control based on stoppage of tonic and clonic movements and absence of epileptic activity in EEG

Secondary

MeasureTime frameDescription
bradycardia6 hoursmonitoring of heart rate
respiratory depression6 hoursmonitoring of respiratory rate
decreased conscious level6 hoursGlasgow Coma Score
hypotension6 hoursmeasurement of blood pressure

Countries

Egypt

Contacts

Primary ContactAmira Darwish, MD
amira.darwish@med.tanta.edu.eg+1026380311

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026